Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Opportunities to Optimize Cancer Policies Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




May
19
Today In Oncology
Patients With IBD May Be at Risk for VTE After Colorectal Cancer Surgery
Ficerafusp Alfa Plus Pembrolizumab: 2-Year Outcomes in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Daraxonrasib for Previously Treated RAS-Mutated Pancreatic Cancer
Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo